- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute myeloid leukaemia (AML)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 2082KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 1598KB)
Gilteritinib – November 2021
Gilteritinib: Tablet 40 mg (as fumarate); Xospata®
Last updated
18 March 2022